Veytsman Irina, Aragon-Ching Jeanny B, Swain Sandra M
Washington Cancer Institute Washington Hospital Center Washington, DC, USA.
Curr Mol Pharmacol. 2013 Jan 8.
The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to anti-angiogenic therapy.
实体瘤继发中枢神经系统（CNS）转移的发生率正在上升。随着实体瘤患者使用更有效的全身治疗，癌症患者寿命延长，最终发生CNS转移的风险更高。然而，由于可用的治疗选择有限，CNS转移的治疗仍然具有挑战性。本文综述了CNS转移的机制、贝伐单抗和其他血管生成抑制剂在复发性和一线CNS转移治疗中的应用，以及抗血管生成治疗耐药性的新问题。
